CYDY - CytoDyn Announces Webcast to Provide Company Update | Benzinga
VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will host an investment community webcast to provide a Company update on Thursday, December 14, 2023. The Company update will include discussion about recent comments from the FDA concerning the clinical hold, an anticipated timeline to respond to the FDA and resolve the clinical hold, the Company's next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.
Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.
| Date: |
| Thursday, December 14, 2023 |
| Time: |
| 1:00 pm PT / 4:00 pm ET |
| Access: |
| https://event.choruscall.com/mediaframe/webcast.html?webcastid=V7AD7TUv |
| Questions: |
| Please submit any questions prior to the webcast, and not later than Noon PT, Monday, December 11, 2023. Questions can be submitted via email to: ir@cytodyn.com. Per CytoDyn's current policy, the presenters will not be able to take live questions during the webcast. |
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until January 14, 2023.
About Dr. Jacob Lalezari
Currently serving as interim CEO, Dr. Lalezari brings over 34 years of industry experience to the Company, including nearly 20 years of past experience with leronlimab, also known as PRO 140. He previously served as ...